GH Research PLC (GHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GH Research PLC (GHRS) has a cash flow conversion efficiency ratio of -0.044x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.26 Million) by net assets ($279.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GH Research PLC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how GH Research PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GHRS liabilities breakdown for a breakdown of total debt and financial obligations.
GH Research PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GH Research PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Qingsong Building Materials and Chemicals Group Co Ltd
SHG:600425
|
0.030x |
|
Frequentis AG
VI:FQT
|
-0.003x |
|
FPT Digital Retail JSC
VN:FRT
|
0.039x |
|
Orezone Gold Corp
TO:ORE
|
0.119x |
|
Permian Basin Royalty Trust
NYSE:PBT
|
72.978x |
|
Shenzhen Tagen Group Co Ltd
SHE:000090
|
-0.001x |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
0.024x |
|
Foosung
KO:093370
|
0.115x |
Annual Cash Flow Conversion Efficiency for GH Research PLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of GH Research PLC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see GHRS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $279.70 Million | $-43.55 Million | -0.156x | +34.10% |
| 2024-12-31 | $178.95 Million | $-42.28 Million | -0.236x | -55.21% |
| 2023-12-31 | $218.97 Million | $-33.34 Million | -0.152x | -45.17% |
| 2022-12-31 | $249.82 Million | $-26.20 Million | -0.105x | -90.20% |
| 2021-12-31 | $277.18 Million | $-15.28 Million | -0.055x | +5.33% |
| 2020-12-31 | $5.67 Million | $-330.00K | -0.058x | +91.94% |
| 2019-12-31 | $400.00K | $-289.00K | -0.723x | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more